Erytech has filed Graspa in Europe for ALL, which could lead to first approval by YE16. In the US, the strategy is evolving, with some protocol amendments potentially accelerating timelines, in addition to the potential for earlier initial approval in the ultra-orphan indication of ‘double-allergic’ ALL patients. Our valuation has been increased to $340m to reflect Erytech retaining certain rights in the US, rather than an outright partnering strategy, including a small commercial
15 Oct 2015
Evolving Eryasp development strategy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evolving Eryasp development strategy
Erytech has filed Graspa in Europe for ALL, which could lead to first approval by YE16. In the US, the strategy is evolving, with some protocol amendments potentially accelerating timelines, in addition to the potential for earlier initial approval in the ultra-orphan indication of ‘double-allergic’ ALL patients. Our valuation has been increased to $340m to reflect Erytech retaining certain rights in the US, rather than an outright partnering strategy, including a small commercial